NCATS supports innovation in new technologies and other clinical and translational approaches that may greatly accelerate the process of transforming laboratory discoveries into new treatments for patients.
NCATS aims to address common barriers in clinical and translational research that scientists nationwide face every day, with the goal of delivering more treatments to more patients more quickly.
NCATS supports innovation in new technologies and other clinical and translational approaches that may greatly accelerate the process of transforming laboratory discoveries into new treatments for patients.
The CTSA Program is designed to strengthen and support the entire spectrum of translational research from scientific discovery to improved patient care.
The RDCRN is designed to advance medical research on rare diseases by facilitating collaboration, study enrollment and data sharing.
Patient and contact registries are key tools that help researchers identify potential clinical study participants, including health volunteers.
NCATS is positioned to help transform the clinical steps of translation and is dedicated to supporting the networks, tools and resources that will improve patient-centered research.
Researchers nationwide face common barriers in clinical and translational research that can delay the development of new interventions for patients in need. These challenges include:
NCATS supports innovative programs, such as the Clinical and Translational Science Awards (CTSA) Program and Rare Diseases Clinical Research Network (RDCRN), to help address these challenges.